恩那度司他改善糖尿病肾病早期肾脏能量代谢紊乱
本研究利用链脲佐菌素诱导的糖尿病大鼠和四氧嘧啶诱导的糖尿病小鼠,分析口服HIF脯氨酰羟化酶抑制剂恩那度司他对糖尿病肾病早期肾脏能量代谢的影响。转录组和代谢组分析显示,恩那度司他可逆转糖尿病肾脏脂肪酸和氨基酸代谢上调及葡萄糖代谢上调,减轻代谢紊乱并缓解氧化应激。
要点
- 恩那度司他可逆转糖尿病早期肾脏脂肪酸和氨基酸代谢上调。
- 恩那度司他减轻糖尿病肾脏糖酵解和三羧酸循环代谢物积累及氨基酸减少。
- 恩那度司他提高谷胱甘肽/谷胱甘肽二硫化物比值,缓解肾脏氧化应激。
核心结论
- HIF稳定化可对抗早期糖尿病肾病中发生的肾脏能量代谢改变。
研究设计与样本
- 使用链脲佐菌素诱导的糖尿病大鼠和四氧嘧啶诱导的糖尿病小鼠进行实验研究。
主要发现
- 转录组分析显示糖尿病肾脏组织中脂肪酸和氨基酸代谢上调,恩那度司他使其下调,而葡萄糖代谢上调。
- 代谢组分析证实糖尿病动物肾脏中糖酵解和三羧酸循环代谢物积累、氨基酸减少,恩那度司他减轻这些代谢紊乱。
- 恩那度司他提高糖尿病动物肾脏中谷胱甘肽与谷胱甘肽二硫化物的比值并缓解氧化应激。
临床怎么用
- 恩那度司他作为HIF稳定剂,可能对早期糖尿病肾病肾脏能量代谢紊乱具有改善作用。
局限性
- 研究仅基于动物模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors, also known as HIF stabilizers, increase endogenous erythropoietin production and serve as novel therapeutic agents against anemia in chronic kidney disease. HIF induces the expression of various genes related to energy metabolism as an adaptive response to hypoxia. However, it remains obscure how the metabolic reprogramming in renal tissue by HIF stabilization affects the pathophysiology of kidney diseases. Previous studies suggest that systemic metabolic disorders such as hyperglycemia and dyslipidemia cause alterations of renal metabolism, leading to renal dysfunction including diabetic kidney disease. Here, we analyze the effects of enarodustat (JTZ-951), an oral HIF stabilizer, on renal energy metabolism in the early stages of diabetic kidney disease, using streptozotocin-induced diabetic rats and alloxan-induced diabetic mice. Transcriptome analysis revealed that enarodustat counteracts the alterations in diabetic renal metabolism. Transcriptome analysis showed that fatty acid and amino acid metabolisms were upregulated in diabetic renal tissue and downregulated by enarodustat, whereas glucose metabolism was upregulated. These symmetric changes were confirmed by metabolome analysis. Whereas glycolysis and tricarboxylic acid cycle metabolites were accumulated and amino acids reduced in renal tissue of diabetic animals, these metabolic disturbances were mitigated by enarodustat. Furthermore, enarodustat increased the glutathione to glutathione disulfide ratio and relieved oxidative stress in renal tissue of diabetic animals. Thus, HIF stabilization counteracts alterations in renal energy metabolism occurring in incipient diabetic kidney disease.
引用
- Hasegawa S, Tanaka T, Saito T, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2019. PMID: 32171449. doi:10.1016/j.kint.2019.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。